Andre B.’s Post

🚨 LAST CHANCE! ⏳ Act now before it's too late! The Clinical Data Disclosure Event is just a month away on March 19-20! Don't wait - FINAL SAVINGS end TONIGHT at midnight! Reserve your spot NOW to secure reduced-rate accommodation options! Don't miss out on this opportunity! ➡️ https://bit.ly/3I0Mojy 📱 Registered attendees gain EXCLUSIVE access to the event app! Stay connected, engaged, and informed. Plus, access valuable content from last year's EU event. 🤝 Network with industry GIANTS like Novartis, Regeneron, Biogen, and more! Rub shoulders with esteemed organizations such as Taylor & Francis Group, The National Institutes of Health, Otsuka Pharmaceutical Companies (U.S.), Sanofi, Merck Group, Amgen, and more! #CDDUS #ClinicalDataDisclosure #Healthcare #Networking #DataTransparency #ProtectingData #Redaction #DisclosureObligations #PlainLanguageSummaries #StrategyDisclosure

🚨 LAST CHANCE! ⏳ Act now before it's too late! The Clinical Data Disclosure Event is just a month away on March 19-20! Don't wait - FINAL SAVINGS end TONIGHT at midnight! Reserve your spot NOW to secure reduced-rate accommodation options! Don't miss out on this opportunity! ➡️ https://bit.ly/3I0Mojy 📱 Registered attendees gain EXCLUSIVE access to the event app! Stay connected, engaged, and informed. Plus, access valuable content from last year's EU event. 🤝 Network with industry GIANTS like Novartis, Regeneron, Biogen, and more! Rub shoulders with esteemed organizations such as Taylor & Francis Group, The National Institutes of Health, Otsuka Pharmaceutical Companies (U.S.), Sanofi, Merck Group, Amgen, and more! #CDDUS #ClinicalDataDisclosure #Healthcare #Networking #DataTransparency #ProtectingData #Redaction #DisclosureObligations #PlainLanguageSummaries #StrategyDisclosure

🚨 LAST CHANCE! ⏳ Act now before it's too late! The Clinical Data Disclosure Event is just a month away on March 19-20! Don't wait - FINAL SAVINGS end TONIGHT at midnight! Reserve your spot NOW to secure reduced-rate accommodation options! Don't miss out on this opportunity! ➡️ https://bit.ly/3I0Mojy 📱 Registered attendees gain EXCLUSIVE access to the event app! Stay connected, engaged, and informed. Plus, access valuable content from last year's EU event. 🤝 Network with industry GIANTS like Novartis, Regeneron, Biogen, and more! Rub shoulders with esteemed organizations such as Taylor & Francis Group, The National Institutes of Health, Otsuka Pharmaceutical Companies (U.S.), Sanofi, Merck Group, Amgen, and more! #CDDUS #ClinicalDataDisclosure #Healthcare #Networking #DataTransparency #ProtectingData #Redaction #DisclosureObligations #PlainLanguageSummaries #StrategyDisclosure

Biopharma's Q1 scorecard is in! Who's up and who's down so far this year? Q1 was a blockbuster for weight-loss drugs, boosting giants like Amgen and AstraZeneca, with Amgen's revenues soaring 22% and AstraZeneca's up by 19%. Novo Nordisk also impressed with a 27% profit spike, though its cautious forecast left investors cold. On the flip side, Biogen, Bristol Myers Squibb, and Johnson & Johnson faced hurdles. Biogen is reshaping its strategy, BMS is cutting costs with a 2,200-person layoff plan, and J&J missed sales targets as patent cliffs loom. We'll continue to keep a close eye on where the industry is heading, so we can better meet your hiring and job search needs. Check out the full story here: https://lnkd.in/egyD7fcC #LifeSciencesIndustry #LifeSciencesTrends #BiotechTrends #PharmaTrends

📈 Biopharma's Q1 2024 Earnings: Winners & Losers 📉 The first quarter of 2024 showcased significant trends in the biopharma industry, with some companies soaring while others faced challenges. Here's a roundup of the winners and losers based on Q1 results! 💼💰 Winners: 🥇 Amgen: Reported solid Q1 financial results, with total revenues of $7.4 billion, driven by product sales growth of 22%. The integration of sales from Horizon' acquisition contributed significantly. 🥈 AstraZeneca: Total revenue surged by 19% to $12.6 billion, fuelled by strong performance in oncology and cardiovascular divisions, especially in emerging markets. 🥉 Novo Nordisk: Posted a 27% increase in operating profit, driven by robust sales in diabetes and obesity care, particularly with GLP-1 products Ozempic and Wegovy. Despite growth, Novo Nordisk's share price dropped by 3%, possibly due to cautious guidance updates. Losers: 👎 Biogen: Faced challenges with declining revenue, particularly in multiple sclerosis products, resulting in a 6.9% YoY drop. The company's transition period includes the redesign of its portfolio and reliance on Leqembi for future revenue. 👎 Bristol Myers Squibb: Despite revenue growth, downgraded EPS guidance and announced layoffs, causing a nearly 8% drop in share price. Patent cliffs and recent acquisitions impact future outlook. 👎 Johnson & Johnson: Missed analyst estimates, with sales growth falling short. Stelara's biosimilar competition adds pressure, despite better-than-expected income. The Q1 earnings season provides valuable insights into the biopharma landscape, showcasing both successes and challenges. Stay tuned for more updates in the industry! 🌐💡 #Biopharma #EarningsSeason #WinnersAndLosers #Healthcare #Finance #BusinessInsights #Pharmaceuticals #Investing #StockMarket #Innovation #Challenges #Opportunities 📊🔬💼

There are fewer things I enjoy talking about more than drug development. For the last few days as part of Teva Pharmaceuticals quarterly earnings report, I’ve been at it nonstop! As a physician in drug development, I get truly excited... completely captivated!... by data that demonstrates the safety and efficacy of a new mode of action. The hope that wells up in me about bringing relief to people living with untreatable or difficult to treat diseases is larger than life. Drug development is my passion and helping patients is my purpose. 2023 has been an incredible year at Teva... we are gaining momentum on our #PivotToGrowth strategy, we are accelerating our late-stage pipeline assets, exploring new science to step up innovation, and we brought our generics business back to growth. These wins don’t happen unless our people are all in. The results speak for themselves, and I couldn’t be prouder of my R&D team and the work we’re doing to push the boundaries of science and progress our pipeline. Thank you to everyone for the part you play in drug development at Teva. We are making it happen! In 2024, we will continue to focus on achieving the exciting clinical milestones of our late-stage pipeline assets, progressing across our key innovative growth drivers, and executing on our complex generics business with new product launches. Watch us go! Ran Meir #TogetherWeCanHelpPatients #TevaPharm #InnovativeMedicines #GenericsInnovators #RandD #TevaRnDThePlaceToBe #Earnings View the full press release: https://lnkd.in/ev3Ns7r9 Forward-looking statements are subject to the cautionary note included in our Q4/Full Year 2023 press release.

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint >> find link to our articles here: https://lnkd.in/dtbB3CAM   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint.    The topics we have discussed during the campaign are linked here and outlined below >> https://lnkd.in/dtbB3CAM   Our overall recommendations to manufacturers are: A) Think about Europe early in the clinical development process to maximise the European opportunity, we recommend it to be no later than in Phase II clinical trials.    B) Understand country level reimbursement processes and pricing potential to help decision-makers think more intelligently about resource allocation in the long term    c) Consider engaging with an experienced partner for European market access to mitigate the potential commercialisation challenges down the road.   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR  

Want to know which Pharma companies are leading R&D budgets? 🧐 Check out the link below. 👀 What is the benefit of this for employees? 💥Increased pipeline & launch potential 💥Increased exposure promoting top quality products 💥Increased value add to HCP’s 💥Increased development opportunities 💥Increased postive patient outcomes 💥Increased reward & satisfaction in your role The list goes on…

L.E.K.'s latest Executive Insight with Pierre Jacquet, M.D., Ph.D. Ricardo Brau Anne Dhulesia details a comprehensive analysis of Biopharma M&A trends and implications for Pharma executives and Boards. With over a decade of experience advising clients on Biopharma M&A, our analyses uncovered key trends in the market that may continue to influence deal-making in 2024 and beyond. Importantly, our work closely examined clinical outcomes and commercial performance of historical M&A deals, highlighting key insights for industry decision-makers to consider for transacting deals in today's environment. Given these learnings, we highlight 5 key strategic priorities to successfully navigate the current M&A environment. Link: